Company
Optos
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
6
510(k), De Novo and PMA
Device trials
16
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Optos, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Optos.
Latest FDA decisions
- P200TE (A10700)510(k)
K233602 · Decided May 9, 2024 · 182 days after receipt
Device type: Tomography, Optical Coherence (OBO) · Ophthalmology
- P200TE (A10700)510(k)
K231673 · Decided Aug 18, 2023 · 71 days after receipt
Device type: Tomography, Optical Coherence (OBO) · Ophthalmology
- P200TxE510(k)
K190732 · Decided Jul 31, 2019 · 132 days after receipt
Device type: Tomography, Optical Coherence (OBO) · Ophthalmology
3 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Modified P200TE Data CollectionRecruiting
NCT07796230 · 50 participants (planned) · Start Jul 29, 2026 · Primary completion Oct 1, 2026
Device: imaging device · For: Retina Disease
Sites: Louisville, Kentucky
- P200TE US Reference Database StudyCompleted
NCT05844852 · 954 participants · Start Mar 14, 2023 · Primary completion Sep 13, 2023
Device: P200TE · For: Normal Eyes
Sites: Anaheim, California; San Diego, California; Venice, Florida · 9 sites in all
NCT06269666 · 100 participants · Start Jan 31, 2024 · Primary completion Oct 9, 2024
Device: P200TxE · For: Retinal Disease
Sites: Louisville, Kentucky
13 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.